Elysium Pharamaceuticals has recently filed its Red Herring Draft Prospectus for an Initial Public offering (IPO) of 66,98,250 equity shares of Rs 10 each at a premium per share at an Issue price in the price band of Rs 25 to 28.Elysium IPO would constitute 32.67% of the fully diluted post issue paid up capital of the company.
Elysium pharmaceuticals Ltd was incorporated in the year 1995 as a formulation unit and later started manufacturing operations in the year 1997.The Company is involved in manufacturing of sterile formulations like Liquid and Dry Parenterals, and non-sterile formulations like Tablets, Capsules, Liquid orals,Ointment, Dry Syrups etc under third party and Contract Manufacturing segment for established Pharma Companies (Bayer,Zydus Cadila,Elder Pharma,Aventis,Torrent,Nicholas Piramal) and Produces its own products Viz.drugs under Ethical segment.
Elysium Pharamaceuticals IPO objectives are as follows
(a) For Setting up a MHRA plant.
(b) To partially repay existing long term secured debt
(c) To meet issue expenses
The Equity Shares offered through this IPOÂ are proposed to be listed on the BSE. The Company has received in-principle approval from the BSE for the listing of Equity Shares . BSE shall be the Designated Stock Exchange.
Elysium Pharmaceuticals IPO Book Running Lead Managers are Canara Bank and Allbank Finance Limited. Registrar for the Elysium Pharma IPO is Intime Spectrum Registry Limited.
Read more information about the IPO in the Elysium-pharmaceuticals-ipo-draft.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
0 comments ↓
There are no comments yet...Kick things off by filling out the form below.
Leave a Comment